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Discussions 
We determined that this patient had definite anti-
NMDAR encephalitis. 
Central nervous system tissue in the teratoma 
might be a trigger of the immune reaction. The 
majority of teratomas are mature cystic ones. 
Immature teratomas (constituting 1% of all 
teratomas) were present in 29% of anti-
NMDAR related cases. Bilateral teratomas 
were present in 14% of cases, comparable to 
12% described in general. 
Seizures, that are common in anti-NMDARE (57–
82%) (2, 5, 15-18), can take place at any time 
during the disease, but tend to occur earlier in 
males (19) and can be confused clinically with  
movement disorders(20). The presence of 
seizures early in the illness course should raise 
diagnostic suspicion. Complex and generalized 
seizures are reported in the majority of cases 
(2), distinguishing anti-NMDARE from most 
causes of viral encephalitis and suggesting that 
seizures are part of the natural history of this 
syndrome(21). For patients with only one 
seizure and no temporal lobe involvement, 
antiepileptic medication may not be strictly 
needed(22). Prolonged follow-up indicates that, 
in most patients, the seizures resolve after the 
encephalitis subsides (9). Valproate, 
levetiracetam, and carbamazepine can be 
selected (18).  
It is important to note that anti-NMDARE cases 
may not follow a strict phasic progression and 
may not include all of the symptomatology 
mentioned, thereby complicating diagnosis (8). 
Diagnostic criteria for probable and definite anti-
NMDARE are presented in Figure 4. 
Objective assays in anti-NMDARE usually are 
nonspecific or normal (2).  
The only specific diagnostic test of anti-
NMDARE  is serum and cerebrospinal 
fluid(CSF) IgG antibodies (23), but serum 
antibodies assays are not as sensitive as CSF 
studies (8, 24), with false negative results in up 
to 14% of cases (24). These results are often 
delayed.  
Brain MRI is abnormal in 30-35% of affected 
patients, mainly showing increased fluid-
attenuated inversion recovery (FLAIR) signal 
involving the cortical, subcortical, or cerebellar 
regions (17). 
Electroencephalography (EEG), as a corollary 
objective test (25),  is often pathologic in anti-
NMDARE, but with  nonspecific abnormalities 
such as diffuse or focal slowing (26).  Focal 
slowing was localized in the fronto-temporal 
(2, 27), and in the temporal region (28). 
Normal EEG were described in 7–14% of cases 
(15, 23), in the early stage of disease or later in 
the recovery phase (26).  EEG may reveal 
extreme versions of the “delta brush pattern” -  
transient  patterns characterized by a slow delta 
wave at 1-3 Hz (15) with superimposed fast 
activity (29). The extreme delta brush that 
appears to be unique and specific to anti-
NMDARE may suggest a more prolonged 
illness, but they are not so frequent (15). Also 
EEG can reveals epileptiform activity (2, 15, 
23, 28, 30, 31) and sinusoidal alpha rhythm as 
an ictal phenomenon (32). 
The majority of patients with teratoma improved 
after tumor resection, also immunotherapy is 
the treatment of choice and involves trials of 
corticosteroids, intravenous immunoglobulins, 
or plasma exchange (8). If patients show 
minimal improvement, the next line of therapy 
is immunosuppression, using rituximab or 
cyclophosphamide, with continued 
immunosuppression (mycophenolate mofetil or 
azathioprine) for at least 1 year (33). The 
recovery could take up to 18 months (17). 
Early identification and treatment has been 
associated with better outcomes (17), less 
frequently associated hippocampal damage 
(34), but, however, up to 25% of patients may 


















The assessment of challenges that intervene in the diagnosis 
and management of anti-N-methyl-D-aspartate receptor 
encephalitis based on a clinical case presentation and  literature 
review. 
  
Material and methods 
We present a case report of a 27 years old female hospitalized with 
confusion, after 2 focal epileptic seizures, with impaired 
awareness and evolution to bilateral tonic-clonic, first life event. 
She was afebrile, without focal neurologic deficits or meningeal 
signs. Medical history without neurological, psychiatric 
pathology or seizures.   From medical recordings, 3 days before 
the admission, the patient was discharged from the gynecology 
department, where she underwent laparoscopic left ovarian 
cystectomy. 
Laboratory parameters were normal. Brain computerized 
tomography (CT) was normal. Electroencephalographically 
identified focal slowing F-T on left at the hyperventilation 
provocation (Fig.2). Histological - mature ovarian cystic 
teratoma 
During hospitalization she developed psychiatric symptoms with 
confusion, agitation, self-aggression, auditory hallucinations, 
orofacial dyskinesias and involuntary movements of the upper 
extremities were observed. Performed EEG excluded non-
convulsive status epilepticus. 
Subsequently, as the psychiatric symptoms progressed even to 
catatonia, she was referred to a psychiatric hospital, preventively 
collecting serum anti-NMDA-R  antibodies (given the 
constellation of personality changes, psychiatric symptoms, 
orofacial dyskinesia and seizures.).  
Anti-NMDA-R antibodies were detected in serum (Fig. 1), so she 
was readmitted to our department, reevaluated by EEG, 
excluded the specific delta brush pattern or non-convulsive 
seizures, performed brain (Fig. 3) and pelvic MRI without 
abnormalities. 
The patient was treated with plasmapheresis (she already had 
Laparoscopic left cystectomy; pathology confirmed mature 
cystic teratoma.), with improvement of the psychoneurological 
condition, then given oral corticosteroids, later tapered, also she 
received antiepileptic drugs – Valproate, taking in count the 
possible temporal lobe involvement. 
At discharge she presented only cognitive disorders (Raven 
Standard IQ test = 75) and difficulties in identifying words. 
Behaviorally and emotionally stable. 
Conclusions 
Anti-NMDAR encephalitis is an increasingly 
recognized, potentially lethal syndrome of 
psychiatric and neuromotor dysfunction in 
patients, often younger in age, who have an 
underlying tumor. 
It is a challenging condition requiring greater 
emphasis of clinical and paraclinical 
manifestations, antibodies panel 
determination, to prevent misdiagnosis and 
to expect a better outcomes.  
The case illustrates the importance of 
suspecting autoimmune encephalitis, 
although the results of antibody testing are 
delayed. 
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Diagnostic criteria for anti-NMDAR  Encephalitis 
Probable anti-NMDA receptor 
encephalitis* 
(three of the following criteria) 
   Rapid onset (less than 
3 months) of at least 




or cognitive dysfunction 









• Decreased level of 
consciousness 
• Autonomic 
dysfunction or central 
hypoventilation 
   At least one of the 
following laboratory 
study results: 
• Abnormal EEG (focal 
or diffuse slow or 
disorganised activity, 
epileptic activity, or 
extreme delta brush) 
• CSF with pleocytosis 
or oligoclonal bands 
 
   Reasonable exclusion 








!!!Diagnosis can also be 
made in the presence of 
three of the above 
groups of symptoms 




  Diagnosis can be made 
in the presence of one 
or more of the six major 
groups of symptoms 
and IgG anti-GluN1 
antibodies,† after 
reasonable exclusion of 
other disorders. 
 
*Patients with a history of herpes simplex virus encephalitis in the previous weeks might have relapsing immune-mediated 
neurological symptoms (post-herpes simplex virus encephalitis).  
†Antibody testing should include testing of CSF. If only serum is available, confirmatory tests should be included (eg, live neurons 
or tissue immunohistochemistry, in addition to cell-based assay). 
Figure 4. Diagnostic criteria for anti-NMDA receptor encephalitis (1) 
Introduction 
Encephalitis represents a severe inflammatory disorder of the 
brain (1).  
Anti-N-methyl-D-aspartate receptor encephalitis (anti-
NMDARE) is an autoimmune encephalitis, caused by 
immunoreactivity against the GluN1 subunit of the 
NMDAR (2). It was first described as a clinical syndrome 
of acute onset psychosis followed by progressive, and 
treatable encephalopathy in 2005 (3), then linked to the 
NMDAR in 2007 by Dalmau et al.(4), and now represents 
one of the most common nonviral encephalitis (5, 6), which 
often remains unrecognized.  
Initially it was associated with ovarian teratomas in women, 
but there are cases without paraneoplastic association (7). It 
can affect all age groups, with lower prevalence in 
individuals greater than 50 years old, and it affects females 
more than males (80% are women) (8, 9). The disease is 
rare, with an estimated incidence of 1·5 per million 
population per year (10). 
Patients develop a polymorphism of symptoms, which may be 
variable and make diagnosis difficult. Initially, in 70% of 
patients, there are an unnoticed prodromal phase, which is 
similar to a viral flu-like illness (11, 12). 
The condition is often recognized in the psychotic phase, with 
delusions, hallucinations, paranoia and agitation, that can be 
difficult to differentiate from a primary psychiatric disease 
(13), or substance-induced psychosis (8). Then the disease 
progress to a state in which catatonia, impaired attention, 
dyskinesias (especially orofacial), seizures (11), and 
autonomic dysfunction(may develop) (8). Self-injuries of 
the tongue, lips, or teeth are common (14). 
 
Figure 2. EEG result of our patient  - focal slowing F T left 
Figure 3. Normal brain MRI scan of our patient 
Figure 1. Anti-NMDA-R antibodies result 
